NO20083709L - Nye krystallinske forbindelser - Google Patents
Nye krystallinske forbindelserInfo
- Publication number
- NO20083709L NO20083709L NO20083709A NO20083709A NO20083709L NO 20083709 L NO20083709 L NO 20083709L NO 20083709 A NO20083709 A NO 20083709A NO 20083709 A NO20083709 A NO 20083709A NO 20083709 L NO20083709 L NO 20083709L
- Authority
- NO
- Norway
- Prior art keywords
- acid
- crystalline compounds
- naphthalene
- new crystalline
- tartaric
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000002253 acid Substances 0.000 abstract 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 2
- 150000007513 acids Chemical class 0.000 abstract 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 abstract 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- 239000001358 L(+)-tartaric acid Substances 0.000 abstract 1
- 235000011002 L(+)-tartaric acid Nutrition 0.000 abstract 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 abstract 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 abstract 1
- 229940092714 benzenesulfonic acid Drugs 0.000 abstract 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 abstract 1
- 239000001530 fumaric acid Substances 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- AUONNNVJUCSETH-UHFFFAOYSA-N icosanoyl icosanoate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCCCCC AUONNNVJUCSETH-UHFFFAOYSA-N 0.000 abstract 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- 239000011976 maleic acid Substances 0.000 abstract 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
Oppfinnelsen angår de nye krystallinske forbindelser A med den generelle formel I: (I), hvor A1, A2, A3, X, Y1, Y2 og Y3 er definert som angitt i krav 1, og som tilveiebringes i form av de fysiologisk akseptable saltene derav med syrer, idet syrene som er valgt fra gruppe B omfatter saltsyre, bromhydrogensyre, svovelsyre, fosforsyre, benzensulfonsyre, p-toluensulfonsyre, maleinsyre, ravsyre, fumarsyre, D-(-)-vinsyre, L-(+)-vinsyre, naftalen-2-sulfonsyre og naftalen-1,5-disulfonsyre, så vel som polymorfene, de respektive solvatene og hydratene. 270 83
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006017827A DE102006017827A1 (de) | 2006-04-13 | 2006-04-13 | Neue kristalline Verbindungen |
| PCT/EP2007/053488 WO2007118819A2 (de) | 2006-04-13 | 2007-04-11 | Neue kristalline verbindungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20083709L true NO20083709L (no) | 2008-10-31 |
Family
ID=38514672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20083709A NO20083709L (no) | 2006-04-13 | 2008-08-28 | Nye krystallinske forbindelser |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7638625B2 (no) |
| EP (1) | EP2010513A2 (no) |
| JP (1) | JP2009533387A (no) |
| KR (1) | KR20090007428A (no) |
| CN (1) | CN101421263A (no) |
| AR (1) | AR060442A1 (no) |
| AU (1) | AU2007239505A1 (no) |
| BR (1) | BRPI0710151A2 (no) |
| CA (1) | CA2648140A1 (no) |
| CO (1) | CO6140057A2 (no) |
| DE (1) | DE102006017827A1 (no) |
| EA (1) | EA200802049A1 (no) |
| EC (1) | ECSP088737A (no) |
| MX (1) | MX2008013158A (no) |
| NO (1) | NO20083709L (no) |
| PE (1) | PE20080735A1 (no) |
| TW (1) | TW200808767A (no) |
| UY (1) | UY30280A1 (no) |
| WO (1) | WO2007118819A2 (no) |
| ZA (1) | ZA200806859B (no) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7491717B2 (en) * | 2005-03-23 | 2009-02-17 | Boehringer Ingelheim International Gmbh | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions |
| PE20080370A1 (es) * | 2006-06-08 | 2008-06-13 | Boehringer Ingelheim Int | Derivados de quinazolinona como antagonistas de cgrp |
| PT3254681T (pt) * | 2012-02-27 | 2019-10-01 | Bristol Myers Squibb Co | Sal de n-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6,7,8,9- tetrahidro-5h-ciclohepta[b]piridin-9-il-4-(2-oxo-2,3- dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1- carboxilato |
| US20220249471A1 (en) * | 2019-06-14 | 2022-08-11 | The Regents Of The University Of California | New therapeutic approach to lung disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0927192T3 (da) | 1996-09-10 | 2004-09-13 | Boehringer Ingelheim Pharma | Modificerede aminosyrer, lægemidler indeholdende disse forbindelser og fremgangsmåder til deres fremstilling |
| DE10250082A1 (de) | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE10250080A1 (de) * | 2002-10-25 | 2004-05-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE102004015723A1 (de) * | 2004-03-29 | 2005-10-20 | Boehringer Ingelheim Pharma | Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
-
2006
- 2006-04-13 DE DE102006017827A patent/DE102006017827A1/de not_active Withdrawn
-
2007
- 2007-04-11 MX MX2008013158A patent/MX2008013158A/es active IP Right Grant
- 2007-04-11 WO PCT/EP2007/053488 patent/WO2007118819A2/de not_active Ceased
- 2007-04-11 PE PE2007000446A patent/PE20080735A1/es not_active Application Discontinuation
- 2007-04-11 EA EA200802049A patent/EA200802049A1/ru unknown
- 2007-04-11 AU AU2007239505A patent/AU2007239505A1/en not_active Abandoned
- 2007-04-11 BR BRPI0710151-1A patent/BRPI0710151A2/pt not_active IP Right Cessation
- 2007-04-11 KR KR1020087027714A patent/KR20090007428A/ko not_active Withdrawn
- 2007-04-11 JP JP2009504732A patent/JP2009533387A/ja active Pending
- 2007-04-11 CN CNA200780012808XA patent/CN101421263A/zh active Pending
- 2007-04-11 CA CA002648140A patent/CA2648140A1/en not_active Abandoned
- 2007-04-11 EP EP07727956A patent/EP2010513A2/de not_active Ceased
- 2007-04-12 UY UY30280A patent/UY30280A1/es not_active Application Discontinuation
- 2007-04-12 US US11/734,520 patent/US7638625B2/en active Active
- 2007-04-12 TW TW096112795A patent/TW200808767A/zh unknown
- 2007-04-13 AR ARP070101573A patent/AR060442A1/es unknown
-
2008
- 2008-08-08 ZA ZA200806859A patent/ZA200806859B/xx unknown
- 2008-08-28 NO NO20083709A patent/NO20083709L/no not_active Application Discontinuation
- 2008-09-15 EC EC2008008737A patent/ECSP088737A/es unknown
- 2008-10-10 CO CO08108825A patent/CO6140057A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200806859B (en) | 2009-08-26 |
| MX2008013158A (es) | 2008-10-22 |
| TW200808767A (en) | 2008-02-16 |
| CA2648140A1 (en) | 2007-10-25 |
| CN101421263A (zh) | 2009-04-29 |
| ECSP088737A (es) | 2008-10-31 |
| EP2010513A2 (de) | 2009-01-07 |
| WO2007118819A3 (de) | 2008-05-29 |
| KR20090007428A (ko) | 2009-01-16 |
| US7638625B2 (en) | 2009-12-29 |
| UY30280A1 (es) | 2007-11-30 |
| JP2009533387A (ja) | 2009-09-17 |
| DE102006017827A1 (de) | 2007-10-18 |
| US20080086003A1 (en) | 2008-04-10 |
| PE20080735A1 (es) | 2008-07-25 |
| BRPI0710151A2 (pt) | 2011-08-02 |
| EA200802049A1 (ru) | 2009-04-28 |
| WO2007118819A2 (de) | 2007-10-25 |
| CO6140057A2 (es) | 2010-03-19 |
| AU2007239505A1 (en) | 2007-10-25 |
| AR060442A1 (es) | 2008-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX367154B (es) | Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico. | |
| PH12012500519A1 (en) | Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors | |
| WO2008055013A3 (en) | 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase | |
| NO20083709L (no) | Nye krystallinske forbindelser | |
| MX2009003823A (es) | Nueva difenilazetidinona sustituida con acido piperazina-1-sulfonico y que tiene propiedades farmacologicas mejoradas. | |
| NO20050921L (no) | Nye fysiologisk aktive substanser | |
| MY148769A (en) | Process for the synthesis of derivatives of 3-amino-tetrahydrofuran-3-carboxylic acid and use thereof as medicaments | |
| EA201270421A1 (ru) | 1,2-дигидро-2-оксохинолиновые соединения в качестве лигандов рецептора 5-нт | |
| WO2008087654A3 (en) | PIPERIDINES AS INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | |
| NO20072755L (no) | Fremgangsmate for fremstilling av 4-(6-klor-2-metylendioksyanilino)-7-2-(4-metylpiperazin-1-yl)etoksy]-5-tetrahydropyran-4-yloksykinazolin, deres mellomprodukter og krystallinske salter derav | |
| MX2012002818A (es) | Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable. | |
| WO2007017728A3 (en) | Novel heterocyclic compounds | |
| UA88643C2 (ru) | Производные амида гетероциклической карбоновой кислоты | |
| Annedi et al. | 3, 5-Disubstituted indole derivatives as selective human neuronal nitric oxide synthase (nNOS) inhibitors | |
| BG108435A (en) | Novel crystalline forms of 4-[4-[4-(hydroxydiphenyl methyl)-1-piperidinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzene acetic acid and its hydrochloride | |
| NO20070845L (no) | Fremgangsmate for fremstilling av losartan | |
| CY1112979T1 (el) | Διαδικασια για την παρασκευη της ενωσης (s)-1-αλκυλ-2',6'-πιπεκολοξυλιδιδιου | |
| WO2007135693A3 (en) | Intermediates useful for the preparation of antihistaminic piperidine derivative | |
| NO20070776L (no) | Forbedret prosess for fremstilling av mirtazapin | |
| NO20060258L (no) | Nematicidale tiazolin-inneholdende fluorobutener | |
| WO2010122580A3 (en) | Piperidine derivatives as inhibitors of renin | |
| DE602006007483D1 (no) | ||
| WO2010012797A3 (en) | Synthesis of 3,4-diaryl-4,5-dihydro-(1h)-pyrazole-1- carboxamidine derivatives | |
| IL194392A0 (en) | Piperidine derivatives useful as serotonin transporter inhibitors and neurokinin-1 receptor antagonists | |
| WO2007004041A3 (en) | New compounds and their pharmaceutical use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |